Eton Pharmaceuticals (NASDAQ:ETON) Price Target Raised to $18.00

Eton Pharmaceuticals (NASDAQ:ETON) had its price target raised by Craig Hallum from $15.00 to $18.00 in a research note released on Wednesday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Separately, HC Wainwright raised their price objective on shares of Eton Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a report on Monday, January 6th.

Eton Pharmaceuticals Stock Up 11.9 %

Shares of ETON opened at $13.44 on Wednesday. The stock has a market cap of $350.13 million, a PE ratio of -61.09 and a beta of 1.38. Eton Pharmaceuticals has a 12-month low of $3.03 and a 12-month high of $15.00. The business has a 50-day simple moving average of $11.64 and a two-hundred day simple moving average of $7.35.

Institutional Investors Weigh In On Eton Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the stock. Point72 Asia Singapore Pte. Ltd. bought a new stake in Eton Pharmaceuticals in the third quarter valued at approximately $54,000. Jane Street Group LLC bought a new stake in shares of Eton Pharmaceuticals in the 3rd quarter valued at $90,000. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Eton Pharmaceuticals by 86.6% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company’s stock worth $390,000 after buying an additional 30,167 shares during the period. Renaissance Technologies LLC raised its stake in Eton Pharmaceuticals by 63.8% during the second quarter. Renaissance Technologies LLC now owns 106,500 shares of the company’s stock worth $350,000 after buying an additional 41,469 shares during the last quarter. Finally, Stonepine Capital Management LLC acquired a new position in Eton Pharmaceuticals in the second quarter valued at $362,000. Institutional investors own 27.86% of the company’s stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.